Described are methods of detecting modified nucleotide bases in a nucleic acid sample using specific DNA glycosylases to excise a modified nucleobase of interest. Prior to glycosylase treatment, DNA target fragment templates are copied by a DNA polymerase to produce a first complementary copy strand that preserves the genetic information of the DNA target fragment. Following glycosylase treatment, the DNA target fragment templates are copied by an abasic bypass polymerase to produce a second complementary copy strand that preserves the epigenetic information of the DNA target fragment. Comparison of the DNA sequences of the two complementary copy strands enables identification of the positions of the modified nucleobases in the DNA target fragment.
Detection of abnormality in specimen image A computer-implemented method of detecting the presence of morphologically abnormal cells in a specimen image comprises: receiving electronic image data representative of a specimen image, the specimen image depicting a plurality of cells; applying an analytical model to each of a plurality of subsets of the image data, each subset corresponding to a respective portion of the specimen image which depicts a single cell, the analytical model configured to output, for each subset of the image data: a value parameterizing a property of the cell; and either a confidence score or an uncertainty score associated with the value, thereby generating output data comprising the plurality of confidence scores or plurality of uncertainty scores; and determining, based on the output data, whether one or more morphologically abnormal cells are likely to be present in the specimen image.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
3.
FILTRATION SYSTEM, METHOD FOR PREDICTING A MAINTENANCE CONDITION OF THE FILTRATION SYSTEM AND METHOD FOR PREDICTING A RECOVERY CONDITION OF THE FILTRATION SYSTEM
A method for predicting a maintenance condition of a filtration system of a diagnostic apparatus or a laboratory analyser at a given time is done by performing the following steps. First a plurality of successive raw permeability values of the permeability of a fluid through the filtration device over a specified measurement period is measured. Then smoothed permeability values are determined by means of a data processing method to reduce the fluctuations of the raw permeability values over time. Afterwards a regression analysis function is applied through the successive permeability values, wherein the regression analysis function comprises fitting parameters being adapted so that the fitting function is fitted to the measured permeability values. Finally, the time, when the regression analysis function will cross a predetermined threshold value is determined, wherein the crossing of the threshold value is judged as a maintenance condition.
A method implemented by one or more computer devices includes providing weakly-supervised neural networks for analysis of histopathology images. The method includes accessing a histopathology image including a slide-level class label. The method includes extracting a plurality of regions of pixels of the histopathology image at a plurality of magnifications. For each of the extracted plurality of regions of pixels, the method further includes inputting the region of pixels into a machine-learning model trained to generate a prediction of a class label for the region of pixels based on the region of pixels and the slide-level class label and outputting the prediction of the class label for the region of pixels. The method includes generating a prediction of one or more tile-level class labels for the histopathology image based on the predictions of class labels for each of the extracted plurality of regions of pixels.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
An insertion device for inserting at least part of a medical device into a subject comprising a chamber for receiving the medical device, an insertion tool for inserting an insertable portion of the medical device, an insertion mechanism, a retraction mechanism for retracting the insertion tool from the subject after insertion, a retaining mechanism for retaining the insertion tool in an end position after retraction, an inner housing comprising the retaining mechanism and the retracted insertion tool in the end position, an inserter housing comprising the insertion mechanism as well as a chamber for receiving the inner housing, wherein the inserter housing is formed of recyclable or biodegradable or compostable material, the insertion device comprises an ejection mechanism to remove the inner housing from the chamber when the insertion tool is retrained within the inner housing by the retaining mechanism, and the ejection mechanism is activatable by the user.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The invention provides viral protease inhibitors having the general formula (I) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
The present invention relates to a method for simulation of quality impact of transportation on a liquid, and a two-dimensional shaker adapted to perform said method.
The present invention relates to a filling apparatus for filling a reusable reservoir of a medical dispensing device, the filling apparatus comprises a receiving portion for a reusable reservoir, a supply container for containing a liquid medication, a first connection port for fluidly connecting an inner volume of the reusable reservoir with the supply container, and a sterilization device that is configured for sterilizing the inner volume of the reusable reservoir. In order to provide an improved sterilization, the filling apparatus further comprises a discharging device for discharging deposit from the inner volume of the inner volume, wherein the sterilization device comprises a radiation source for providing a radiation for sterilizing the reusable reservoir. The reusable reservoir is housed in a radiation chamber.
A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises: a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128); b) at least one sample recognition step comprising localizing at least one sample re- gion on the reflective target (128); and c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser ir- radiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser de- sorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p.ex. fermetures étanches au vide; Dispositions pour le réglage externe des composants électronoptiques ou ionoptiques
Computer-implemented methods for analysing a medical image are provided, the method comprising: obtaining a medical image; inputting the image into a machine learning model, the machine learning model trained with training medical images, by: obtaining a plurality of smaller image segments from the training medical images; obtaining an image embedding for each image segment; and processing the embeddings using one or more attention mechanisms comprising a B-cos transform. Related methods, products and systems are described.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
15.
COMBINATION THERAPY OF A GPRC5D TCB AND PROTEASOME INHIBITORS
The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with IMiDs. The combination therapy may further comprise a glucocorticosteroid.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
An in-vitro diagnostic (IVD) analyzer (200) comprising at least one sensor (212) located in a flow-through sensor path (211) of detecting unit and requiring at least one oxygenated calibration fluid (221', 222') for calibration is herein disclosed. The IVD analyzer (200) further comprises a fluid-supply unit (220) comprising at least one deoxygenated calibration fluid (221, 222), a fluid-selection valve (230) and at least one oxygenation tubing (215, 216) having two ends connected to the fluid-selection valve (230) as a loop, wherein the oxygenation tubing (215, 216) comprises oxygen-permeable walls, and wherein the IVD analyzer (200) further comprises a pump (240) and a controller (250) configured to control the pump (240) and the fluid-selection valve (230) for transporting deoxygenated calibration fluid (221, 222) into the oxygenation tubing (215, 216), to wait a predetermined time required for oxygenation of the deoxygenated calibration fluid (221, 222) via oxygen uptake from ambient air through the tubing walls, and to transport the thereby obtained oxygenated calibration fluid (221', 222') into the sensor path (211) for calibration of the at least one sensor (212). A respective automatic method of calibrating at least one sensor (212) is herein also disclosed.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G01N 33/96 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
Herein is reported a method for classifying cells in a cell mixture, wherein the mixture comprises T-cells and B-cells, comprising the steps of first applying at least labelled antibodies binding to F-actin, MHCII and CD3 to the cell mixture to obtained a labelled cell mixture, wherein the antibodies are each labelled with a dye, wherein the dyes have different (non-overlapping) emission wavelengths, second acquiring at least one image of the cell mixture, and third classifying the cells in the cell mixture to be an isolated cell if the cell is a single cell, is F-Actin positive and is MHCII positive and CD3 negative, or is MHCII negative and CD3 positive, or to be a doublet or multiplet of cells if the cell is an aggregate of two or three cells, is F- Actin positive, MHCII positive and CD3 positive.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Computer-implemented methods of providing a disease diagnosis or prognosis for a patient are described. These comprise generating individual networks, each individual network comprising a plurality of nodes and edges between pairs of the nodes, wherein each node is indicative of a biological factor in biological data for an individual, and each edge is indicative of a relationship between a pair of biological factors corresponding to the nodes that the edge connects for the respective individual; determining the value of one or more similarity metrics between one or more individual networks generated for the patient and one or more individual networks generated for other individuals in the plurality of individuals; and predicting a diagnosis or prognosis for the patient using a machine learning model that takes as input the values of one or more similarity metrics.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
A diagnostic device configured to count a number of swallows of a user, the device comprising: at least one processor; a user interface; one or more sensors associated with the device; and a memory storing computer-readable instructions that, when executed by the at least one processor, cause the diagnostic device to: prompt, via the user interface, the user to provide a user input via the one or more sensors associated with the device each time the user is at a predetermined point during a swallowing action; receive a plurality of inputs via the one or more sensors, each user input corresponding to a respective time at which the user is at a predetermined point during the swallowing action; generate, in response to receiving each user input, a timestamp associated with the respective user input; apply a counting model to data comprising the plurality of generated timestamps, wherein the counting model is configured to calculate a number of swallows of a user by counting the total number of timestamps in the data comprising the plurality of generated timestamps; and outputting the calculated number of swallows.
Methods of sequencing by expansion and related improvements to the sequencing of surrogate polymers in a nanopore are described. The surrogate polymer is formed from a template nucleic acid molecule. A surrogate polymer includes multiple units. Each unit includes a reporter code portion. The reporter codes correspond to the different nucleotides. surrogate polymers may get stuck in the nanopore. Embodiments described herein address these stuck surrogate polymers. In order to allow for multiple reads on the surrogate polymer, a processive consensus technique can be applied. The surrogate polymer may be moved a few units forward and then fewer units backward so that some of the same reporter codes are identified again. This method allows for multiple reads of the same reporter codes. The surrogate polymer eventually passes through the nanopore in the forward direction. Periodically, higher clearing voltages may be applied to clear any stuck surrogate polymer in the nanopore.
Respiration rate measurement A diagnostic device configured to measure a respiration rate of a user, the device comprising: at least one processor; a user interface; one or more sensors associated with the device; and a memory storing computer-readable instructions that, when executed by the at least one processor, cause the diagnostic device to: prompt, via the user interface, the user to provide a user input via the one or more sensors associated with the device each time the user is at a predetermined point during an inhalation cycle; receive a plurality of user inputs via the one or more sensors, each user input corresponding to a respective time at which the user is at a predetermined point during an inhalation cycle; generate, in response to receiving each user input, a timestamp associated with the respective user input; apply a respiration rate model to data comprising the plurality of generated time stamps, wherein the respiration rate model calculates a respiration rate of the user based on the generated time stamps; and output the calculated respiration rate.
A diagnostic device configured to assess respiratory function, lung capacity, abdominal strength and/or thoracic strength or impairments of a subject, the diagnostic device comprising: a processor; a microphone; and a memory storing computer- readable instructions that, when executed by the processor, cause the diagnostic device to: prompt the subject to perform a diagnostic task of making a long "aaah" sound for a predetermined duration; receive audio data associated with the diagnostic task via the microphone; extract, from the audio data, digital biomarker data; and apply an analytical model to the extracted digital biomarker data, the analytical model configured to generate an output indicative of the respiratory function, lung capacity, abdominal strength and/or thoracic strength or impairments of the subject
G10L 25/03 - Techniques d'analyses de la parole ou de la voix qui ne se limitent pas à un seul des groupes caractérisées par le type de paramètres extraits
G10L 25/78 - Détection de la présence ou de l’absence de signaux de voix
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G10L 25/66 - Techniques d'analyses de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour extraire des paramètres en rapport avec l’état de santé
A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
A61B 5/22 - Ergométrie; Mesure de la force musculaire ou de la force d'un coup musculaire
A diagnostic device configured to assess the speech function of a subject, the diagnostic device comprising: at least one processor; a microphone; and a memory storing computer-readable instructions that, when executed by the at least one processor, cause the diagnostic device to: prompt the subject to perform a diagnostic task of speaking aloud; receive, via the microphone, audio data associated with the diagnostic task; extract, from the audio data, digital biomarker data associated with the speech function of the subject; and applying a speech function assessment model to the digital biomarker data, the speech function assessment model configured to generate an output indicative of the speech function of the subject.
G10L 25/03 - Techniques d'analyses de la parole ou de la voix qui ne se limitent pas à un seul des groupes caractérisées par le type de paramètres extraits
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G10L 25/66 - Techniques d'analyses de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour extraire des paramètres en rapport avec l’état de santé
G10L 25/78 - Détection de la présence ou de l’absence de signaux de voix
25.
IMPROVED PROTEASE-ACTIVATABLE T CELL BISPECIFIC ANTIBODIES
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A diagnostic device (110) for monitoring at least one body tissue (134) of a patient is disclosed. The diagnostic device (110) comprises: a. at least one bracelet (112) configured to be strapped around a body part (132) of the patient; b. at least one electromechanical actuator (114) configured for actively varying a circumference of the bracelet (112); c. at least one measurement unit (126) configured for determining at least one item of information on an electrical power applied to the electromechanical actuator (114) and at least one item of circumference information on the circumference of the bracelet (112); and d. at least one evaluation unit (128) configured for determining at least one item of information on a status of the body tissue (134) from the item of information on the electrical power applied to the electromechanical actuator (114) and the item of circumference information, wherein the evaluation unit (128) is configured for determining a point of contact at which the circumference of the bracelet (112) corresponds to the circumference of the body part. Further, a method of monitoring at least one body tissue (134) of a patient is disclosed.
A61B 5/107 - Mesure de dimensions corporelles, p.ex. la taille du corps entier ou de parties de celui-ci
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire
The present invention generally relates to novel protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates comprising (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavage site, wherein the linker has a length of 20 to 45 amino acids, wherein the masking moiety is covalently attached to the IL-2 polypeptide through the linker, wherein the masking moiety is capable of binding to the IL-2 polypeptide thereby reversibly concealing the IL-2 polypeptide, wherein the masking moiety comprises a second protease cleavage site, wherein the masking moiety does not conceal the IL-2 polypeptide upon cleavage at the first and/or the second protease cleavage site. The present invention also relates to polynucleotides encoding such protease-activatable interleukin-2 (IL-2) polypeptides and immunconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates of the invention, and to methods of using these protease-activatable interleukin-2 (IL-2) polypeptides and immunoconjugates in the treatment of disease.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
28.
SUPPLY CHAIN OPTIMIZATION WITH REINFORCEMENT LEARNING
The present invention relates to systems and methods to optimize a supply chain. Various embodiments of the present invention relate to systems and methods to optimize a multi-distribution-level supply chain and, more specifically but not limited, to systems and methods to optimize a multi-distribution-level supply chain via a machine-learning model based on reinforcement learning.
The invention provides compounds having the general formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein A, L, n, and R1to R3 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C09B 11/24 - Phtaléines contenant des groupes amine
C09B 23/04 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH un seul groupe CH, p.ex. cyanines, isocyanines, pseudocyanines
C09B 23/10 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre pair de groupes CH
This automated analysis device comprises an analyzing unit 40 for analyzing a sample, and a control device 20 for controlling operations of each mechanism of the analyzing unit 40, wherein the control device 20 calculates a waiting time that a user should wait until the sample or a consumable required to analyze the sample is replaced, on the basis of a time at which the sample or the consumable is to be used last, in an analysis schedule created at a time point at which a replacement request for the sample or the consumable is accepted. By this means, the present invention provides an automated analysis device, and a method for operating the automated analysis device, capable of improving work efficiency.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
31.
METHOD FOR SEPARATING FULL AND EMPTY AAV PARTICLES
Herein is reported a method for separating full and empty recombinant adeno- associated virus particles using an anion exchange chromatography step, wherein the method comprises a sequence of a applying a solution comprising empty and/or full rAAV particles to an anion exchange chromatography material inside a chromatography column, a first isocratic step, a first linear gradient, a second isocratic step and a second linear gradient, wherein the empty recombinant adeno- associated virus particles are eluted during the first linear gradient and the full recombinant adeno-associated virus particles are eluted during the second linear gradient. In certain embodiments, the solution applied in the first isocratic step comprises about (65) mM of the buffer substance, about (10) mM of the elution salt, about (2) mM of the salt and has a pH value of about 9.4. In certain embodiments, the solution applied in the second isocratic step comprises about (65) mM of the buffer substance, about (90) mM of the elution salt, about (2) mM of the salt and has a pH value of about 9.4. In certain embodiments, the buffer substance is N-(1,1-Dimethyl- (2)-hydroxyethyl)-(3)-amino-2-hydroxypropane sulfonic acid, the elution salt is tetramethyl ammonium chloride, and the salt is magnesium chloride.
B01D 15/16 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives au conditionnement du fluide vecteur
B01D 15/36 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p.ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
B01D 15/42 - Adsorption sélective, p.ex. chromatographie caractérisée par le mode de développement, p.ex. par déplacement ou par élution
The present invention is Claim a positive control system (1) for container closure integrity (CCI) testing comprising a container and an adapter. The container (3) has a hollow interior (31), an opening (35) and an edge (331) surrounding the opening (35). The adapter (2) has a first coupling structure (21) configured to be connected to a flow reduction holder (4), and a second coupling structure (22). The second coupling structure (22) of the adapter (2) is vacuum tightly glued to the edge (331) of the container (3). The adapter (2) is configured such that the interior (31) of the container (3) is accessible from the first coupling structure (21).
G01M 3/32 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par mesure du taux de perte ou de gain d'un fluide, p.ex. avec des dispositifs réagissant à la pression, avec des indicateurs de débit pour récipients, p.ex. radiateurs
G01M 3/22 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par détection de la présence du fluide à l'emplacement de la fuite en utilisant des révélateurs particuliers, p.ex. teinture, produits fluorescents, produits radioactifs pour soupapes
33.
NOVEL PHAGOCYTOSIS ASSAY COMBINING A SYNTHETIC CELL DEATH SWITCH AND A PHAGOCYTOSIS REPORTER SYSTEM
The present invention relates to a recombinant expression vector encoding an inducible cell death switch, a pH-stable fluorophore and a pH-sensitive fluorophore. Moreover, the invention relates to cells comprising said recombinant expression vector as well as their use in an in vitro phagocytosis assay.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention related to a multidimensional LC system for analysing antibodies. The system provides multiple different measurement samples from a single sample, for example, the system may provide a native antibody sample for measurement, a reduced antibody sample for measurement and digested sample for peptide mapping from a single sample. The system has a fractionation module, a reduction module, a digestion module, a separation module and at least a first and a second splitter for splitting the flow.
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
Prediction of pharmacokinetic properties of chemical compounds A computer-implemented method of generating a machine-learning model configured to predict the value of one or more pharmacokinetic parameters of a pharmaceutical compound having a chemical structure comprises: receiving training data comprising a plurality of records, each record comprising: data encoding the chemical structure of a pharmaceutical compound; and the values of one or more pharmacokinetic parameters obtained from measurements taken from a human or animal subject after administration of the compound to the human or animal subject; and training the machine-learning model using the training data. Computer-implemented methods of utilizing the generated machine-learning model, particularly in a drug design context, are also provided.
The present invention relates to double-stranded RNA molecules conjugated to at least one conjugate moiety for topical administration to the eye, and pharmaceutical compositions thereof. The double-stranded RNA molecules are complementary, such as fully complementary, to targets expressed in the eye, and are capable of inhibiting expression of targets expressed in the eye. The double-stranded RNA molecules can be used in the treatment of conditions and diseases of the eye.
The present invention is directed to a packaging member (1) for a photosensitive drug substance being made of a substantially stiff sheet-like material which defines an outer packaging surface (20) and an inner packaging surface (30). The packaging member (10) comprises a front wall member (1), a rear wall member (2) and at least four side wall members (3, 4, 5, 6). The inner packaging surface (30) of at least one of the front wall member (1), the rear wall member (1) and/or the at least four side wall members (3, 4, 5, 6) comprises a colour being adapted to provide for a light absorption of at least about 50 %.
B65D 5/02 - Réceptacles de section transversale polygonale rigides ou semi-rigides, p.ex. boîtes, cartons ou plateaux, formés en pliant ou montant un ou plusieurs flans de papier en pliant ou montant un seul flan pour former un corps tubulaire avec ou sans pliage subséquent, ou par addition d'éléments séparés, pour fermer les extrémités du corps
B65D 5/56 - Revêtements ou recouvrements intérieurs
B65D 81/30 - Adaptations pour empêcher la détérioration ou l'altération du contenu; Applications au réceptacle ou au matériau d'emballage d'agents de conservation des aliments, de fongicides, d'insecticides ou de produits repoussant les animaux en excluant la lumière ou toute autre radiation extérieure
B65D 5/50 - Parties insérées dans le réceptacle, qui en font partie intégrante ou qui lui sont fixées pour former des garnitures intérieures ou extérieures Éléments internes de support ou de protection du contenu
39.
INSPECTION SYSTEM AND METHOD FOR A CLOSED MEDICAL CONTAINER
An inspection system (1.3) is operative to inspect a medical container containing a liquid. The inspection system (1.3) comprises an actuator (1.6) operative to displace a light source and/or detector of an optical system (1.5) relative to a sample holder (1.4) during data acquisition. Acquired data are analyzed to detect and/or determine characteristics of a particle in the medical container.
A computer-implemented method is provided for generating a trained TTS-GAN which may be used to generate synthetic longitudinal data for use in survival analysis, a clinical trial or clinical research. The TTS-GAN is configured to generate synthetic time-series data based on synthetic context data generated using a machine-learning model by virtue of being trained using training data comprising real context data and added noise data. A technique for executing survival analysis is also provided, which relies on the synthetic longitudinal data.
The present disclosure relates to the fields of molecular biology, more specifically antigen-binding molecule technology. The present disclosure also relates to methods of medical treatment and prophylaxis, particularly cellular immunotherapy.
-tert-tert-butyl-3-[(1-methyltetrazol-5- yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol for use in the treatment of diabetic retinopathy, and its methods of treatment thereof.
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 9/14 - Vasoprotecteurs; Antihémorroïdaux; Médicaments pour le traitement des varices; Stabilisateurs capillaires
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to novel antibodies which bind to human CB2. Further, the invention relates to a method of detecting changes in cell surface CB2 expression by flow cytometry in response to the treatment with a CB2 agonist. The method allows to assess and monitor target engagement of CB2 agonists thus supporting pre-clinical and clinical development of CB2 agonists.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
44.
THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF
Described are antisense oligonucleotides comprising one or more α-L-threofuranosyl (TNA) nucleosides linked to an adjacent nucleoside via a phosphodiester (PO) internucleoside linkage, as well as methods to modulate the properties of antisense oligonucleotides by the introduction of such TNA nucleosides. These are particularly applicable to antisense gapmer oligonucleotides.
The present disclosure is directed to compositions and kits for PCR amplification. The present disclosure is also directed to methods of amplifying nucleic acid molecules to improve upon uniformity of coverage and/or to reduce GC bias during downstream sequencing operations.
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
Provided herein are compounds of Formula (I):
Provided herein are compounds of Formula (I):
and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
Methods for quantifying amyloid related imaging abnormalities (ARIA) in a brain of a patient are provided. The method includes accessing a set of one or more brain-scan images associated with the patient, and inputting the set of one or more brain-scan images into one or more machine-learning models. The one or more machine-learning models are trained to generate a segmentation map based on the set of one or more brain-scan images, the segmentation map including a plurality of pixel-wise class labels corresponding to a plurality of pixels in the segmentation map. The one or more machine-learning models are further trained to generate a classification score based on the segmentation map. The method thus includes detecting ARIA in the brain of the patient based on the classification score.
Methods for the rapid detection of the presence or absence of Monkeypox Virus (MPXV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the MPXV F3L gene and the MPXV B21R gene, along with kits are provided that are designed for the detection of MPXV.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
The invention relates to novel compounds having the general formula (I) wherein the substituents R1, R2, R3, R411 are as defined above, composition including the compounds and methods of using the compounds.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
Methods for segmenting and detecting amyloid related imaging abnormalities (ARIA) in a brain of a patient are provided. The method includes accessing a set of one or more brain-scan images associated with the patient, and inputting the set of one or more brain-scan images into one or more machine-learning models trained to generate a segmentation map based on the set of one or more brain-scan images. The segmentation map includes a plurality of pixel-wise class labels corresponding to a plurality of pixels in the segmentation map, in which at least one of the plurality of pixel-wise class labels includes an indication of ARIA in the brain of the patient. The method further includes outputting a quantification of ARIA in the brain of the patient based at least in part on the segmentation map.
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 271/12 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant deux atomes d'azote et un atome d'oxygène comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 293/10 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et de sélénium, ou d'azote et de tellure, avec ou sans atomes d'oxygène ou de soufre, comme hétéro-atomes condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 407/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/02 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles
55.
CONTAINER CLOSURE INTEGRITY TESTING METHOD AND SYSTEM
A container closure integrity (CCI) testing method for testing tightness of a stopper closure of a syringe (7), wherein the syringe has a syringe body (71) with a longitudinal axis, a hollow interior extending between an open first axial end and a second axial end with an orifice (712), and an elastic stopper (73) provided through the open first axial end into the hollow interior such that a chamber (74) is formed between the stopper (73) and the second axial end, comprises: providing the syringe (7) in a gas environment comprising a detection gas; moving the stopper (73) inside the hollow interior of the syringe body (71); and sensing for detection gas exiting the chamber (74) of the syringe (7) while moving the stopper (73) inside the hollow interior of the syringe body (71).
G01M 3/22 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par détection de la présence du fluide à l'emplacement de la fuite en utilisant des révélateurs particuliers, p.ex. teinture, produits fluorescents, produits radioactifs pour soupapes
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
The present invention provides a method comprising the steps of a) providing a nucleic acid comprising 5fC, 5hmC, or 5caC, b) providing one reactant comprising two reactive groups wherein the first reactive group is capable of reacting with the formyl hydroxymethyl or carboxyl group, and the second reactive group is a nucleophilic group, c) reacting said first reactive group with the formyl, hydroxymethyl or carboxyl group thereby resulting in a modified 5fC, 5hmC, or 5caC, d) reacting said second reactive group with the C6 position of said modified 5fC, 5hmC, or 5caC, thereby obtaining a bicyclic or tricyclic molecule comprising a 5,6-di-hydro Cytosine entity, and e) deaminating said 5,6-di-hydro Cytosine entity to a 5,6 di-hydro-Uracil entity.
The present invention relates to the prevention or mitigation of adverse effects related to gene therapy, such as the formation of anti-drug antibodies. Specifically, the invention relates to the prevention or mitigation of such side effects using a tyrosine kinase inhibitor such as dasatinib.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
59.
PROCESS FOR MANUFACTURING AN ANTIBIOTIC MACROCYCLIC PEPTIDE
The invention relates to a novel process for manufacturing 4-[(11S,14S,17S)-14-(4-Aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid (I), or a pharmaceutically acceptable salt thereof. The invention further relates to certain synthetic intermediates that are useful for the novel process according to the invention. The process according to the invention is particularly suitable for large-scale manufacturing of the compound of formula (I) under GMP conditions.
C07K 5/09 - Tripeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p.ex. Lys, Arg
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein Y, R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the componds and methods of using the compounds.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. clothiapine, diltiazem
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the componds and methods of using the compounds.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. clothiapine, diltiazem
The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I) wherein R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. clothiapine, diltiazem
The present invention relates to pharmaceutical compositions comprising 5-ethyl-4- methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
64.
METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FACTOR X
An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
C07K 16/36 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, R1, R2, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein R1, R2and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/554 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. clothiapine, diltiazem
The present invention relates to compounds of formula (I), wherein A1to A7and W are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
69.
MACHINE LEARNING ENABLED LOCALIZATION OF FOVEAL CENTER IN SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY VOLUME SCANS
A method and system for localizing a foveal center of a retina. An optical coherence tomography (OCT) volume for a retina of a subject is received. The OCT volume includes a plurality of OCT B-scans of the retina. A three-dimensional image input is generated for a model using the OCT volume. The model includes a three-dimensional convolutional neural network. The model is used to generate a foveal center position that includes three-dimensional coordinates for a foveal center of the retina based on the three-dimensional image input. The foveal center position may be used to generate an output that can be used in screening for retinal disease, diagnosing retinal disease, predicting treatment response, and/or managing retinal disease treatment.
The present disclosure relates generally to machine learning. More particularly, the present disclosure relates to federated learning. Moreover, the present invention relates to a system for federated learning, a computer program and a computer-readable medium.
A biomedical knowledge graph system, the system including a computer database of records, the records comprising nodes of biomedical entities and connections between the entities representing biomedical relationships. One or more processors are programmed and configured to extract data from a plurality of data sources, determine biomedical entities and relationships between the entities based on analyzing the data, wherein analyzing the data comprises searching for predetermined identifiers or patterns in the data. Based on the determined biomedical entities, assigning each biomedical entity to a cluster of biomedical entity types. The one or more processors are configured to identify a context for each of the identified biomedical entities based on the assigned cluster and based on elements of the expression of the biomedical data within which the entity is expressed. Based on the identified context and type of the biomedical entity, incorporating records of nodes and connections between nodes into the knowledge graph, the nodes representing biomedical entities and the connections representing biomedical relationships between the entities structured according to the predefined schema.
The present invention relates to a method (200) of continuously in vivo detecting at least one analyte in a bodily fluid over a time span, an analyte sensor system (100) for in vivo continuously detecting at least one analyte in a bodily fluid over a measurement time span, a computer program and a computer-readable storage medium. The method (200) makes use of at least one analyte sensor (102) comprising at least one working electrode (104), configured for performing at least one electrochemical detection reaction with the analyte, and at least one further electrode (106), the further electrode (106) comprising at least one redox material composition, the redox material composition comprising silver and silver chloride, the method (200) comprising the following steps: monitoring at least one standard sensor signal (132) derived by using the analyte sensor (102) in a standard operation mode, comparing the standard sensor signal (132) with at least one threshold, thereby determining if a change of an operation mode of the analyte sensor (102) from the standard operation mode into an economy operation mode is required.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p.ex. par des moyens polarographiques invasifs, p.ex. introduits dans le corps par un cathéter
A61B 5/1495 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang Étalonnage ou test des sondes in vivo
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5and R6 are as described herein, composition including the compounds and methods of using the compounds.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, R5and R6 are as described herein, composition including the compounds and methods of using the compounds.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
The invention provides a method of determining whether a subject has a neurological dysfunction associated with a signal in a particular electroencephalogram (EEG) or magnetoencephalogram (MEG) frequency range, the method comprising: obtaining an EEG power spectrum from the subject; and obtaining a metric quantifying the power in the power spectrum in the particular frequency range, wherein the metric summarises the power in said frequency range corrected using an estimate of the power in said frequency range that is attributable to background signal that is specific to said frequency range, wherein the metric is indicative of the presence and/or severity and/or direction of a neurological dysfunction. Related methods and devices are also described.
A61B 5/291 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p.ex. détection des ondes delta, thêta, alpha, bêta ou gamma
A61B 5/245 - Détection de champs biomagnétiques, p.ex. de champs magnétiques produits par des courants bioélectriques spécialement adaptée aux signaux magnétoencéphalographiques [MEG]
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/16 - Dispositifs pour la psychotechnie; Test des temps de réaction
The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody, atezolizumab, and bevacizumab.
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, X and Y are as described herein, composition including the compounds and methods of using the compounds.
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
79.
NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES
The invention relates to novel compounds having the general formula (I) wherein R1, R2, X1, X2, X3 and W are as described herein, composition including the compounds and methods of using the compounds.
C07C 311/44 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons ayant des atomes de soufre de groupes sulfonamide et des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07D 213/76 - Atomes d'azote auxquels est lié un second hétéro-atome
C07D 217/22 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle contenant l'azote
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p.ex. chorée, dyskinésie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to compounds of formula (I), wherein R1to R7, A1and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
The invention relates to novel compounds having the general formula (I) wherein R4, R512311 are as described herein, composition including the compounds and methods of using the compounds.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Herein is reported a polypeptide-linker-nucleic acid conjugate, wherein the linker comprises a 3-amino propanamide unit, a 2,6-diamino hexanoic acid amide unit, and a 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, wherein the polypeptide comprises a C-terminal lysine residue, and wherein the nucleic acid comprises an oxygen linked to a phosphorous atom of the oxidation state V at the 5' or 3' terminus, wherein the 3-amino group of the 3-amino propanamide unit and the carboxy function of the lysine residue of the polypeptide are linked by/form an amide bond, the carboxy function of the 3-amino propanamide unit and the alpha amino group of the 2,6-diamino hexanoic acid amide unit are linked by/form an amide bond, the 6-amino group of the 2,6-diamino hexanoic acid amide unit is a nitrogen of the 1,2,3-triazole element of the 1,4,5,5a,6,6a,7,8- octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, and the oxygen linked to the phosphorous atom of the nucleic acid is covalently linked to the cyclopropane element of the 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3- triazole unit.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p.ex. séquences de liaison peptidiques vulnérable aux protéases
C12P 13/00 - Préparation de composés organiques contenant de l'azote
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4 and W are as described herein, composition including the compounds and methods of using the compounds.
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p.ex. chlorazanil, mélamine
84.
LEUKOTRIENE A4 HYDROLASE (LTA4H) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.
G01N 33/88 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des prostaglandines
85.
METEORIN-LIKE PROTEIN (METRNL) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Meteorin-like protein (METRNL) in a sample of the subject.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
86.
FIBROBLAST GROWTH FACTOR BINDING PROTEIN 1 (FGFBP1) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
87.
DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
The present invention relates to oligonucleotides for editing a target nucleic acid, as well as conjugates, salts and pharmaceutical compositions thereof. The invention also relates to uses of such oligonucleotides, conjugates, salts and pharmaceutical compositions in methods for editing target nucleic acids and in medical uses and methods of treatment of disease.
The invention relates to novel compounds having the general formula I wherein R1, R21233 and W are as described herein, composition including the compounds and methods of using the compounds.
C07D 221/04 - Systèmes cycliques condensés en ortho ou en péri
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
90.
NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES
The invention relates to novel compounds having the general formula I wherein R1, R21233 and W are as described herein, composition including the compounds and methods of using the compounds.
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/485 - Dérivés du morphinane, p.ex. morphine, codéine
A61K 31/5383 - 1,4-Oxazines, p.ex. morpholine condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p.ex. chorée, dyskinésie
A61P 25/18 - Antipsychotiques, c. à. d. neuroleptiques; Médicaments pour le traitement de la manie ou de la schizophrénie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
91.
RATIO BETWEEN LTA4H AND METRNL IN THE ASSESSMENT OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total LTA4H in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentration determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.
G01N 33/88 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des prostaglandines
92.
RATIO BETWEEN FGFBP1 AND METRNL IN THE ASSESSMENT OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total FGFBP1 in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentrations determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.
G01N 33/563 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des fragments d'anticorps
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
93.
DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The disclosure refers to a method of operating a laboratory sample distribution system having a plurality of carriers (4) configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) assigned to the laboratory devices (3) and providing support to the plurality of carriers (4); and a driving device (13) configured to move, in response to driving control signals, the plurality of carriers (4) between plane positions (5) provided on the transport plane (1). The method comprises: prior to moving the carriers (4) on the transport plane (1), pre-determining off-line routes (6) on the transport plane (1) by one or more processors of a data processing device, the pre-determining comprising: determining a model representing the transport plane (1) with plane locations (5') and location-to-location movements between plane locations (5') associated to the plurality of carriers (4) calculating an optimized set of off-line routes between pairs of plane locations from the plurality of plane locations (5') using the model, the calculating comprising solving an optimization problem in which routes between the pairs of plane locations are simultaneously optimized; and providing the optimized set of off-line routes as off-line routes (6) on the transport plane (1); and controlling the driving device (13) such that the carriers (4) are moved along the pre-determined off-line routes (6) on the transport plane (1). Furthermore, a laboratory sample distribution system, and a laboratory automation system are provided.
G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs
B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
95.
METHOD OF OPERATING A LABORATORY SAMPLE DISTRIBUTION SYSTEM, LABORATORY SAMPLE DISTRIBUTION SYSTEM, AND LABORATORY AUTOMATION SYSTEM
The disclosure refers to a method of operating a laboratory sample distribution system having: a plurality of carriers (4) having a number of n (n>3) carriers (4) each configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) configured to support to the plurality of carriers (4), wherein the transport plane (1) comprises a plurality of interconnected transport modules comprising a plurality of plane fields (5); and a driving device (13) configured to control movement of the plurality of carriers (4) along individual routes between the plurality of plane fields (5). The method com- prises: moving the plurality of carriers (4) along the individual routes on the transport plane (1), wherein the moving, for each carrier, comprises executing at least once steps of reserving a route segment along the individual route, the route segment being provided by one or more plane fields of the plurality of plane fields (5), and moving the carrier (4) along the route seg- ment; and preventing, for the plurality of carriers (4), a deadlock arrangement on the transport plane in which the plurality of carriers (4) block each other from further movement along the individual routes (6). The preventing is further comprising: determining, at a present operation time, a potential deadlock arrangement for the plurality of carriers (4) on the transport plane (1) at a future operation time, wherein the potential deadlock arrangement is assigned a number of n deadlock plane fields occupied by the plurality of carriers (4) in case of the potential dead- lock arrangement; for a first carrier from the plurality of carriers (4) moving along a first individ- ual route, reserving a first route segment ending with a first end plane field; and assigning a non-reserve flag to a next plane field which is next to the first end plane field along the first individual route. Further, a laboratory sample distribution system, and a laboratory automation system are provided.
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs
B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques
The present invention relates to compounds of formula (I), wherein R1to R3, M, A, Y and W are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
Herein is reported a method for lysing recombinant AAV particle producing mammalian cells comprising the step of bringing a mammalian cell cultivation broth in contact with an alkyl polyglucoside detergent, preferably Triton CG 110, and thereby lysing recombinant AAV particle producing mammalian cells and releasing the produced recombinant AAV particles, wherein the mammalian cell cultivation broth comprises cultivated recombinant AAV particle producing mammalian cells and the cultivation medium used for the cultivation of said recombinant AAV particle producing mammalian cells (spent medium).
The present invention relates to a mutant ketoreductase, a nucleic acid encoding the mutant ketoreductase, a vector comprising the nucleic acid, a method for the enzymatic reduction of a prochiral ketone and the formation of a chiral alcohol with the mutant ketoreductase, the use of the mutant ketoreductase for the preparation of chiral alcohols as well as the use of the method for the preparation of pharmaceutically active morpholine compounds.
The present invention relates to a medical infusion device comprising a reservoir for holding a liquid medicament, a cannula assembly, a fluid line, a drive mechanism, a dispensing member for dispensing medicament from reservoir through the fluid line and the cannula assembly, and a leakage determining module. For a more convenient determination of leakage of liquid medicament, the leakage determining module comprises an electronic probe that is configured for receiving odor molecules and/or flavor molecules of the liquid medicament and in that the leakage determining module further comprises evaluation electronics that is configured to determine presence of odor and/or flavor of the liquid medicament based on readings of the at least one electronic probe.
The present invention relates to compounds of formula (I), wherein R1to R3 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
C07F 9/6561 - Composés hétérocycliques, p.ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
